Pharma Powerhouse Gedeon Richter Stays on Track for 2025 Growth
August 7, 2025
4,855
Gedeon Richter Nyrt. reported first-half results in line with its annual targets, prompting the company to maintain its 2025 growth forecast, CEO Gábor Orbán said Wednesday in Budapest.
Adjusting for currency fluctuations, the pharmaceutical giant anticipates approximately 10% growth in both revenue and adjusted EBIT for the year. Pharmaceutical manufacturing, which accounts for 98% of sales, rose 11% in the second quarter to 237.5 billion HUF (cc. 598 million EUR/1 EUR = 397 HUF), bringing half-year revenue to 458 billion HUF.
The gynecology division accelerated notably with 19% growth in Q2, fueled by strong demand across Western and Eastern Europe. Key therapeutic areas—including infertility, menopause, and endometriosis treatments—achieved double-digit gains, while contraceptive sales also outperformed last year’s figures.
Meanwhile, the generics segment expanded 7.7% to surpass 130 billion HUF, despite a slowdown in volume growth during the quarter.
Gábor Orbán, Gedeon Richter’s CEO; Photo: Hungary Today
Research and development expenditures rose 8%, accounting for 11% of revenue. CFO László Kovács highlighted that currency headwinds weighed on net profit, which stood at 120 billion HUF for the first half—a 13% decline compared to 2024.
Orbán addressed the ongoing uncertainty surrounding U.S. tariff policies and underscored challenges to European pharmaceutical competitiveness, exacerbated by the global minimum tax.
He also expressed concern over a state-supported rival’s investment in Gödöllő, which aims to recruit biotech specialists currently employed by Richter.
While no new acquisitions are planned this year, the company remains vigilant in assessing potential opportunities. Richter shares are traded on the Budapest Stock Exchange’s premium segment, with prices fluctuating between 9,500 HUF and 11,260 HUF over the past year.
Hungary’s pharmaceutical industry is a key pillar of the national economy and global competitiveness. believes Foreign Minister Péter Szijjártó. Continue reading
Via MTI; Featured image: Facebook/Richter Gedeon Nyrt.
A legjobb élmény biztosítása érdekében olyan technológiákat használunk, mint a cookie-k az eszközadatok tárolására és/vagy eléréséhez. Ha beleegyezik ezekbe a technológiákba, akkor olyan adatokat dolgozhatunk fel ezen az oldalon, mint a böngészési viselkedés vagy az egyedi azonosítók. A hozzájárulás elmulasztása vagy visszavonása bizonyos funkciókat és funkciókat hátrányosan érinthet.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
